MX2021008070A - Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions. - Google Patents

Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions.

Info

Publication number
MX2021008070A
MX2021008070A MX2021008070A MX2021008070A MX2021008070A MX 2021008070 A MX2021008070 A MX 2021008070A MX 2021008070 A MX2021008070 A MX 2021008070A MX 2021008070 A MX2021008070 A MX 2021008070A MX 2021008070 A MX2021008070 A MX 2021008070A
Authority
MX
Mexico
Prior art keywords
peptide analogs
conotoxin peptide
treatment
pain
inflammatory conditions
Prior art date
Application number
MX2021008070A
Other languages
Spanish (es)
Inventor
Shawn Iadonato
Jose Mercado
Eric J Tarcha
Jeffrey J Posakony
Original Assignee
Kineta Chronic Pain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain Llc filed Critical Kineta Chronic Pain Llc
Publication of MX2021008070A publication Critical patent/MX2021008070A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an a9- containing nicotinic acetylcholine receptor (nAChR) (e.g., the α9α10 subtype of the nAChR) in a subject.
MX2021008070A 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions. MX2021008070A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/012307 WO2020142102A1 (en) 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Publications (1)

Publication Number Publication Date
MX2021008070A true MX2021008070A (en) 2021-10-13

Family

ID=65244618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008070A MX2021008070A (en) 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions.

Country Status (15)

Country Link
EP (1) EP3906253A1 (en)
JP (1) JP2022522935A (en)
KR (1) KR20210116505A (en)
CN (1) CN113966339A (en)
AU (1) AU2019418319A1 (en)
BR (1) BR112021013302A2 (en)
CA (1) CA3125383A1 (en)
CL (1) CL2021001775A1 (en)
CO (1) CO2021008845A2 (en)
CR (1) CR20210363A (en)
IL (1) IL284574A (en)
MX (1) MX2021008070A (en)
PE (1) PE20211734A1 (en)
SG (1) SG11202106847SA (en)
WO (1) WO2020142102A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033485A (en) 2021-09-01 2023-03-08 삼성전자주식회사 Storage device and operating method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2008011006A2 (en) 2006-07-18 2008-01-24 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc Biologically active peptidomimetic macrocycles
TWI777260B (en) * 2014-11-07 2022-09-11 美商奇尼塔慢性疼痛有限責任公司 Modifications and uses of conotoxin peptides

Also Published As

Publication number Publication date
WO2020142102A1 (en) 2020-07-09
WO2020142102A9 (en) 2020-11-19
CR20210363A (en) 2021-12-10
IL284574A (en) 2021-08-31
EP3906253A1 (en) 2021-11-10
AU2019418319A1 (en) 2021-07-22
BR112021013302A2 (en) 2021-09-14
SG11202106847SA (en) 2021-07-29
PE20211734A1 (en) 2021-09-06
KR20210116505A (en) 2021-09-27
CN113966339A (en) 2022-01-21
CO2021008845A2 (en) 2021-10-29
JP2022522935A (en) 2022-04-21
CL2021001775A1 (en) 2022-05-27
CA3125383A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2018003331A (en) Administration of deuterated cftr potentiators.
MX2019007156A (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2019012884A (en) Combination therapy.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
JOP20190191A1 (en) Therapeutic dendrimers
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
MX2021006156A (en) Compounds useful in hiv therapy.
MX2022010748A (en) Methods of treating apol-1 dependent focal segmental glomerulosclerosis.
MX2021003681A (en) Benzimidazole derivative for use in the treatment of inflammatory disorders.
MX2022015629A (en) Use of vibegron to treat overactive bladder.
CR20210480A (en) Pharmaceutical formulations
MX2019005104A (en) Zinc-y-pga compositions and methods for treating cancer.
PH12020500666A1 (en) Pladienolide compounds and their use
RU2016137289A (en) FGF-18 COMPOUND DIAGRAM
MX2021008070A (en) Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions.
MX2021002878A (en) Cd73 inhibitors and pharmaceutical uses thereof.
MX2021002012A (en) Methods of treating acute stress disorder and posttraumatic stress disorder.
EA201991531A1 (en) METHODS OF TREATMENT OF LINACLOTIDE COMPOSITIONS WITH DELAYED DELIVERY
MX2018012716A (en) Pegylated bioactive peptides and uses thereof.
MX2021006654A (en) Use of cocculus hirsutus extract for treating dengue.
TW201129361A (en) Methods for treating pain
EA202092190A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE CONSTRUCTION
MX2022008827A (en) Plant extract composition for the treatment of cardiovascular and metabolic diseases.